Evgen Pharma PLC Services Agreement with APTrans

TIDMEVG

Evgen Pharma PLC

13 February 2017

13 February 2017

RNS REACH

Evgen Pharma plc

("Evgen Pharma" or the "Company")

Services Agreement with Drug Development Consortium

Evgen Pharma, a clinical stage drug development company focused on cancer and neurological conditions, is pleased to announce the signing of a services agreement with APTrans to support the ongoing development of lead product, SFX-01. APTrans is a consortium of drug development companies based in the Biohub at Alderley Park, Cheshire.

APTrans works with clients to help them transform promising molecules into valued medicines and was founded on the complementary vision, values and expertise of three founding companies:

-- Aptus Clinical, a specialist provider of Contract Clinical Research Services focusing on innovative study design, high quality conduct and exemplary delivery of early phase oncology studies

-- Apconix, a toxicology company at the forefront of innovative thinking in nonclinical toxicology and safety science

-- Seda Pharmaceutical Development Services, an integrated pharmaceutical development and clinical pharmacology service that maximises value build

Dr Stephen Franklin, Founder and CEO of Evgen Pharma, said: "We are delighted to have found a flexible way to access specialist technical expertise and operational support to complement our existing internal capabilities to support the ongoing development of our lead product, SFX-01. We selected this excellent group of providers as our partners as they have a proven track record of working well together and they are all co-located at the Biohub where we too have a presence."

Ned Wakeman, Director, Biohub at Alderley Park, commented: "The APTrans initiative is a tangible example of how the environment here can accelerate business value. The companies within APTrans all spun out from AstraZeneca, participated in business acceleration programmes, and are thriving in their own right. We are passionate about nurturing an open and collaborative environment where like-minded companies can work, socialise and support each other, and are proud to share in the combined successes of these great companies."

Enquiries:

 
 Evgen Pharma plc                         c/o [phone] 
 Dr Stephen Franklin, CEO 
 www.evgen.com 
 
  Buchanan 
  Mark Court, Sophie Cowles, Stephanie 
  Watson                                      [phone] 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and has its registered office at the Liverpool Science Park and is a virtual tenant at the Biohub at Alderley Park, Cheshire, UK. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. For further information please visit www.evgen.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADMGMZMZNGNZZ

(END) Dow Jones Newswires

February 13, 2017 02:00 ET (07:00 GMT)